NCT00847483已完成4 期
A Comparison of Latanoprost (Xalatan) With Travoprost (Travatan) and Bimatoprost (Lumigan) in Patients With Elevated Intraocular Pressure. A Twelve-week, Masked Evaluator, Phase IV, Multicenter Study in the United States. (Xalatan vs Travatan vs Lumigan).
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.1 个研究点 分布在 1 个国家目标入组 375 人开始时间: 2002年1月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 375
- 试验地点
- 1
- 主要终点
- To compare the IOP reducing effect of latanoprost (Xalatan) versus travoprost (Travatan) versus bimatoprost (Lumigan) over a twelve-week period.
研究概览
简要总结
Compare the IOP lowering properties of latanoprost, travoprost and bimatoprost
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Unilateral or bilateral primary open angle glaucoma (POAG), exfoliative glaucoma, pigmentary glaucoma or ocular hypertension (glaucoma is defined as either visual fields defect or glaucomatous changes of the optic nerve head in association with elevated intraocular pressure. Ocular hypertension is defined as IOP ≥ 21 mmHg at diagnosis).
- •Is currently receiving (at the screen visit) or has received topical monotherapy or dual therapy (within the past 6 months) for POAG or ocular hypertension.
- •Required washout periods are 4 weeks for -adrenergic antagonists, prostaglandin analogues (including latanoprost, unoprostone, travoprost and bimatoprost) and 2 weeks for adrenergic agonists, and 5 days for cholinergic agonists and carbonic anhydrase inhibitors, prior to the baseline visit.
- •Mean 8 AM IOP ≥ 23 mmHg at the baseline visit for all patients. Patients should be assigned treatment only after the 8 PM IOP is obtained.
- •Visual acuity (best corrected) equal to or better than 20/200 (Snellen). ETDRS charts may be used and converted to Snellen units.
- •Informed Consent: Signed Informed Consent is obtained at the screen visit.
- •Able to adhere to treatment/visit planUnilateral or bilateral primary open angle glaucoma, capsular glaucoma, pigmentary glaucoma or ocular hypertension.
- •Open angle glaucoma appearing more than 6 months after cataract surgery is recognized as primary open angle glaucoma. (individuals requiring treatment bilaterally must fulfill eligibility criteria for both eyes.)
- •IOP of 22mmHg or higher obtained during the pre-study period.
排除标准
- •Ocular conditions
- •Closed/barely open anterior chamber angle or history of acute angle closure. (Patients who are diagnosed with POAG after a successful peripheral iridotomy may be enrolled).
- •History of ALT (Argon Laser Trabeculoplasty) within 3 months prior to the screen visit (the unlasered eye may be enrolled as the study eye).
- •History of any ocular filtering surgical intervention (the unfiltered eye may be enrolled as the study eye).
- •Ocular surgery (on the globe of the eye only), or inflammation/infection within 3 months prior to screen visit. (Applies to both fellow and study eyes.)
- •Hypersensitivity to benzalkonium chloride or to any other component in latanoprost (Xalatan), travoprost (Travatan) or bimatoprost (Lumigan).
- •Other abnormal ocular conditions or symptoms preventing the patient from entering the study, in the investigator's clinical judgement.
- •Other conditions
- •Use of systemic medication known to affect IOP (i.e., alpha-adrenergic agonists, beta-adrenergic antagonists, calcium channel blockers, ACE inhibitors and/or angiotensin II receptor blockers, or corticosteroids), unless the patient and the medication dosage have been stable for three months prior to the screen visit and the dosage is not expected to change during the study.
- •Women of childbearing potential (WOCBP) who are not using contraceptive methods. Women of childbearing potential are defined as women who are not surgically sterile or not postmenopausal (at least 12 months without a menstrual period). Contraception is defined as abstinence, having a vasectomized partner, or the ongoing use of approved oral, injectable or implanted contraceptives, a barrier method, or an IUD.
- •Pregnancy. Women of childbearing potential (WOCBP) must have a negative urine pregnancy test at the screen visit and baseline visit.
- •Nursing mothers General
- •Use of any investigational medication within 30 days prior to screen visit.
研究组 & 干预措施
Latanoprost
Active Comparator
干预措施: latanoprost 0.005% ophthalmic solution (Drug)
Travoprost
Active Comparator
干预措施: Travoprost 004% sterile ophthalmic solution (Drug)
Bimatoprost
Active Comparator
干预措施: Bimatoprost .03% sterile ophthalmic solution (Drug)
结局指标
主要结局
To compare the IOP reducing effect of latanoprost (Xalatan) versus travoprost (Travatan) versus bimatoprost (Lumigan) over a twelve-week period.
时间窗: 12 weeks
The mean change since baseline of Week 12 IOP measured at the time of peak (8:00AM) drug effect.
时间窗: 12 weeks
次要结局
- To study the safety variables within and between all treatment groups over 12 weeks(12 weeks)
- The mean change since baseline of Week 12 IOP measured at the times of peak (8:00AM) and trough (8:00PM) drug effects evaluated by race. The percentage of patient withdrawals from the study(12 weeks)
- The mean change since baseline of Week 12 IOP measured at the time of trough (8:00PM) drug effect. The mean percentage change since baseline of diurnal IOP at Week 12.(12 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Comparison of travoprost and latanoprost plus timolol fixed combinations in open-angle glaucoma and ocular hypertension patients previously treated with dorzolamide plus timolol fixed combination.primary open angle glaucoma, normal tension glaucoma and ocular hypertension patientsJPRN-UMIN000005974Department of Ophthalmology, National Defense Medical College70
已完成
不适用
Crossover comparative study of latanoprost/timolol fixed combination with combined therapy comprised of latanoprost and timololglaucoma, ocular hypertensionJPRN-UMIN000005426Department of Ophthalmology, Gifu University Graduate School of Medicine40
已完成
不适用
Comparable study between bimatoprost and latanoprost/timolo fixed combination in primary open angle glaucoma patientsPrimary open angle glaucoma patientsJPRN-UMIN000004595Department of Ophthalmology, Kyoto Prefectural University of Medicine80
已完成
不适用
Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)Ocular HypertensionOpen-Angle GlaucomaNCT00716742Allergan1,099
撤回
不适用
The Effects of Cosopt® Vs Xalacom® on Ocular Hemodynamics and Intraocular Pressure (IOP) in Primary Open-angle Glaucoma (POAG)Ocular HypertensionOpen-Angle GlaucomaNCT00815373Meir Medical Center